NCT06764121Active, not recruiting
Impact of Canadian Haskap Berry Powder on Hypertension and Acuity in Women's Health
Impact of Haskalife(TM) Canadian Haskap Berry Powder Formulation on Hypertension and Acuity in Women's Health
Source: ClinicalTrials.gov · Last updated 4 Dec 2025
Brief summary (registry, in English)
Haskap berries are rich in cyanidin-3-O-glucoside (C3G), which has been shown in vitro to enhance endothelial function. Previous clinical studies suggest haskap berry supplementation may improve cognition, mood, blood pressure, and athletic performance, but research is limited. This trial aims to contribute to the growing body of evidence on the effects of haskap berry supplementation. The trial is a 2-period, randomized, double-blinded, cross-over design lasting 16 weeks. During the first period (weeks 0-6), participants will receive either haskap berry powder or a control powder. A 4-week washout period follows (weeks 7-10), where no powder is consumed. In the second period (weeks 11-16), participants will receive the powder they did not consume in the first period.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 32 (actual)
- First submitted
- 2 Jan 2025
- Start date
- 3 Apr 2025
- Primary completion date
- 26 Mar 2026
- Lead sponsor
- University of Manitoba
- Diseases
- High blood pressure
- NCT number
- NCT06764121
What you commit to
- Study type: Interventional
- Participants enrolled: 32
- From 3 Apr 2025 to the primary completion date, 26 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving chemotherapy;
- Use of medications containing pseudoephedrine or other anti-inflammatory drugs, and the use of cyclosporine or tacrolimusin;
- Cardiovascular diseases including stroke, congestive heart failure, myocardial infarction, unstable angina pectoris, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, and transient ischemic attack within six months before screening;
- Any medical condition, uncontrolled systemic disease, or concurrent illness that would hinder study compliance or jeopardize the participant's safety, based on the investigator's opinion
Other illness
- Gluten allergies, celiac disease, or gluten intolerance;
- Allergic to berries;
- Risk of epileptic seizures;
- Any visual impairments, uncorrected vision problems, eye disorders, or injuries
Age
- Any of the following visual impairments: diabetic retinopathy, age-related macular degeneration, glaucoma, or cataract;
Other
- Biological male;
- Inability to consume treatment product;
- Inability to provide written informed consent;
- Any form of motor impairments;
Who the study is looking for
- Willing and able to provide informed consent to participate in the trial;
- Biological female who is at least 35 years of age;
- A waist circumference of at least 35 inches;
- Average systolic blood pressure between 120 and 150 mmHg;
- Average diastolic blood pressure between 75 and 100 mmHg
Age in the registry: 35 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Richardson Centre for Food Technology and Research Coordinator of this site? Confirm its status | Winnipeg | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.